Lead Sponsor

GlaxoSmithKline

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•HIV-infected.
•Screening viral load at least 5000copies/mL.
•Total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.
•Able to receive a ritonavir-boosted protease inhibitor during treatment studies.
•Women of childbearing potential must use specific forms of contraception.

•Acute laboratory abnormalities.
•History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.
•Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment or observational studies.
•Pregnancy or breastfeeding women.
•Recent participation in an experimental drug trial.
•Prior use of a CCR5 or CXCR4 antagonist.
•Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness.
•Current use of certain medications may exclude participation in this study.
•Additional qualifying criteria and laboratory test requirements to be assessed by study physician.

Related studies

NCT06857071 · Undiagnosed HIV Infection, Populations That Are Reluctant to Test for HIV, and more

NCT06627764 · Substance Abuse, Intimate Partner Violence (IPV), and more

NCT06900829 · HIV Infection, HIV, and more

NCT04142047 · HIV, HIV Infections

NCT06694805 · HIV Infections

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140